Filing Flows

Filing Flows › Tenon Medical (TNON) › Next earnings date

Tenon Medical (TNON) earnings on Nov 12, 2026: what to expect

Tenon Medical (TNON) is expected to report earnings on Nov 12, 2026, in 4 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$4.22 (−$5.62 to −$2.83, 2 estimates) on revenue of $1.6M, against −$14.00 and $1.2M a year ago. It beat the EPS estimate in 25% of the quarters on record; Filing Flows' model gives it a 58% chance of beating next time.

Report dateNov 12, 2026
Days to go4
EPS estimate−$4.22
Revenue estimate$1.6M
Beat rate25%

What to watch

Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:

Tenon Medical: revenue lines, growth year over year, Q2 2026Tenon Medical: revenue lines, growth year over year, Q2 2026Revenue+127%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$14.00 on revenue of $2.5M, against the analysts' −$4.22.

The last report

Tenon Medical reported revenue of $1.3M for the second quarter 2026 (+127% Y/Y), net loss $4.0M. How it makes money → · Every quarter →

Tenon Medical: EPS against the estimate, last 4 reportsTenon Medical: EPS against the estimate, last 4 reportsEstimateReported−$12.95−$14.00Nov 25−$12.60−$7.70Mar 26−$10.68−$10.85May 26−$8.40−$12.35Aug 26
Latest (Aug 26): Estimate −$8.40, Reported −$12.35.

Tenon Medical's latest quarter

Tenon Medical, Q2 2026: revenue $1.3M (+127% year over year), operating margin -262.2%, net loss $4.0M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.

Questions

When does TNON report earnings?

Tenon Medical is expected to report on Nov 12, 2026.

What are analysts expecting from Tenon Medical?

EPS of −$4.22 and revenue of $1.6M for the quarter.

Does Tenon Medical usually beat earnings?

It beat the consensus EPS estimate in 25% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.